CyPass recall tops August ophthalmology news

Alcon’s decision to voluntarily recall its CyPass micro-stent from the global market was the most-read article on Healio.com/OSN in August.

Here are the month’s top five stories:

 

Alcon calls for surgeons to stop implanting CyPass micro-stent

According to a company press release, the decision was based on safety data from the COMPASS-XT study, which found a statistically significant difference in endothelial cell loss at 5 years after surgery in patients who received the device in conjunction with cataract surgery compared to those who underwent cataract surgery alone. Read more.

 

FDA approves Oxervate, the first drug to treat neurotrophic keratitis

Oxervate (cenegermin), developed by Dompé farmaceutici SpA, is the first FDA approved drug for the rare disease, which can cause loss of corneal sensation and impair corneal health. Patients with neurotrophic keratitis can experience corneal thinning, ulceration and perforation in severe cases. Read more.

 

Continuous glucose monitor may help reduce incidence of diabetic eye disease

Studies have shown that a reduction in HbA1c has a concomitant reduction in diabetic retinopathy. Read more.

 

FDA approves Sun Pharma s dry eye treatment

Cequa (cyclosporine ophthalmic solution 0.09%), the highest FDA-approved concentration of cyclosporine A and the first to incorporate nanomicellar technology, is indicated to increase tear production. Read more.

 

FDA approves Eylea 12-week dosing for wet AMD

The FDA has approved a supplemental biologics license application for a 12-week dosing schedule of Eylea injection in wet age-related macular degeneration patients. Read more.

Alcon’s decision to voluntarily recall its CyPass micro-stent from the global market was the most-read article on Healio.com/OSN in August.

Here are the month’s top five stories:

 

Alcon calls for surgeons to stop implanting CyPass micro-stent

According to a company press release, the decision was based on safety data from the COMPASS-XT study, which found a statistically significant difference in endothelial cell loss at 5 years after surgery in patients who received the device in conjunction with cataract surgery compared to those who underwent cataract surgery alone. Read more.

 

FDA approves Oxervate, the first drug to treat neurotrophic keratitis

Oxervate (cenegermin), developed by Dompé farmaceutici SpA, is the first FDA approved drug for the rare disease, which can cause loss of corneal sensation and impair corneal health. Patients with neurotrophic keratitis can experience corneal thinning, ulceration and perforation in severe cases. Read more.

 

Continuous glucose monitor may help reduce incidence of diabetic eye disease

Studies have shown that a reduction in HbA1c has a concomitant reduction in diabetic retinopathy. Read more.

 

FDA approves Sun Pharma s dry eye treatment

Cequa (cyclosporine ophthalmic solution 0.09%), the highest FDA-approved concentration of cyclosporine A and the first to incorporate nanomicellar technology, is indicated to increase tear production. Read more.

 

FDA approves Eylea 12-week dosing for wet AMD

The FDA has approved a supplemental biologics license application for a 12-week dosing schedule of Eylea injection in wet age-related macular degeneration patients. Read more.